<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="case-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2023.1253821</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>IgG4-associated hypophysitis coexisting with MALT lymphoma and gangliocytoma: first case report and literature review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zou</surname>
<given-names>Dongbo</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2015662/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Li</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2416215/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Cheng</surname>
<given-names>Jingmin</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<xref rid="fn00020" ref-type="author-notes"><sup>&#x2020;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Ma</surname>
<given-names>Yuan</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<xref rid="fn00020" ref-type="author-notes"><sup>&#x2020;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Neurosurgery, General Hospital of Western Theater Command</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Rheumatology and Immunology, The Second People's Hospital of Chengdu</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0001">
<p>Edited by: Krystallenia I. Alexandraki, National and Kapodistrian University of Athens, Greece</p>
</fn>
<fn fn-type="edited-by" id="fn0002">
<p>Reviewed by: Clara Limback, Oxford University Hospitals, United Kingdom; Dabiao Zhou, Capital Medical University, China</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Jingmin Cheng, <email>sjwkuser@163.com</email></corresp>
<corresp id="c002">Yuan Ma, <email>tianfu_47@163.com</email></corresp>
<fn fn-type="equal" id="fn00020">
<p><sup>&#x2020;</sup>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>09</day>
<month>11</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1253821</elocation-id>
<history>
<date date-type="received">
<day>06</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>10</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Zou, Jiang, Yang, Cheng and Ma.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Zou, Jiang, Yang, Cheng and Ma</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>IgG4-related or IgG4-associated hypophysitis is a rare disease characterized by the infiltration of IgG4-positive plasma cells into pituitary gland tissue. Gangliocytomas in the sellar region are also extremely rare and are associated with pituitary adenomas in the majority of cases. Sellar mucosa-associated lymphoid tissue (MALT) lymphoma is an exceedingly rare condition. In this study, we present a case of IgG4-associated hypophysitis coexisting with MALT lymphoma and gangliocytoma. However, to elucidate the potential pathophysiological relationship, it is imperative to gather additional cases of IgG4-related hypophysitis accompanied by MALT lymphoma and gangliocytoma.</p>
</abstract>
<kwd-group>
<kwd>IgG4-related hypophysitis</kwd>
<kwd>MALT lymphoma</kwd>
<kwd>gangliocytomas</kwd>
<kwd>sellar region</kwd>
<kwd>headaches</kwd>
<kwd>vision loss</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="23"/>
<page-count count="6"/>
<word-count count="3494"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Neuro-Oncology and Neurosurgical Oncology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<title>Introduction</title>
<p>IgG4-related hypophysitis, a rare condition affecting the sellar region, has been increasingly reported in recent years. It can manifest as an isolated disease or as part of a multisystemic disorder. However, it is worth noting that the majority of IgG4-related hypophysitis cases are not associated with other neoplastic diseases (<xref ref-type="bibr" rid="ref1">1</xref>).</p>
<p>In this report, we present a biopsy-confirmed case of IgG4-associated hypophysitis coexisting with MALT lymphoma and gangliocytoma.</p>
</sec>
<sec sec-type="case" id="sec2">
<title>Case</title>
<p>In May 2018, a 53-year-old female presented with a 1-month history of worsening right visual acuity and headaches. Prior to this, she had been in good health. Endocrine assessment revealed abnormal secretion of prolactin and thyroid hormone (<xref ref-type="table" rid="tab1">Table 1</xref>). MRI examination of the pituitary gland revealed a well-defined soft tissue mass measuring 3.2&#x2009;cm&#x2009;&#x00D7;&#x2009;1.9&#x2009;cm&#x2009;&#x00D7;&#x2009;1.9&#x2009;cm, located in sella, suprasellar area, and right cavernous sinus. Additionally, there were small patchy short T1 signal shadows within the lesion, which displayed heterogeneous enhancement. The mass encased the right internal carotid artery and compressed the right optic chiasm, resulting in an unclear pituitary stalk (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Visual examination showed decreased vision and visual field defects in the right eye, whereas the left eye exhibited normal vision. Surgical resection was recommended to alleviate optic nerve compression. However, the patient declined surgery and opted for continued follow-up.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Endocrine assessment for the first time.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Report projects</th>
<th align="center" valign="top">Results</th>
<th align="center" valign="top">Normal values</th>
<th align="center" valign="top">Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Prolactin</td>
<td align="center" valign="top">86.71</td>
<td align="center" valign="top">3.34&#x2013;26.7</td>
<td align="center" valign="top">ng/mL</td>
</tr>
<tr>
<td align="left" valign="top">FT3</td>
<td align="center" valign="top">2.33</td>
<td align="center" valign="top">2.38&#x2013;4.34</td>
<td align="center" valign="top">pg/mL</td>
</tr>
<tr>
<td align="left" valign="top">FT4</td>
<td align="center" valign="top">0.68</td>
<td align="center" valign="top">0.9&#x2013;1.76</td>
<td align="center" valign="top">ng/dL</td>
</tr>
<tr>
<td align="left" valign="top">Cortisol</td>
<td align="center" valign="top">7.0 (08:00)&#x2212;2.37 (16:00)&#x2212;4.61 (00:00)</td>
<td align="center" valign="top">Morning 6.7&#x2013;22.6&#x2009;&#x03BC;g/dL; Afternoon 0&#x2013;10&#x2009;&#x03BC;g/dL</td>
<td align="center" valign="top">Ug/dL</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p><bold>(A&#x2013;C)</bold> The first MRI examination showed that the lesion invaded the cavernous sinus, with obvious enhancement after enhancement and compression of the optic chiasm. <bold>(A)</bold> Coronal T1 enhancement; <bold>(B)</bold> Sagittal T2 imaging; and <bold>(C)</bold> Axial T1 imaging.</p>
</caption>
<graphic xlink:href="fneur-14-1253821-g001.tif"/>
</fig>
<p>In January 2019, the patient was readmitted due to severe binocular vision loss and debilitating headaches. Ophthalmic vision examination revealed further deterioration in the right eye, with vision reduced to perceiving only light. Simultaneously, vision in the left eye was limited to half a meter in front. Pituitary hormone assessment indicated persistently disturbed prolactin and thyroid hormone secretion (<xref ref-type="table" rid="tab2">Table 2</xref>). MRI examination demonstrated significant enlargement of the sellar and suprasellar lesions, now measuring 4.7&#x2009;cm&#x2009;&#x00D7;&#x2009;2.8&#x2009;cm&#x2009;&#x00D7;&#x2009;4.8&#x2009;cm, with uniform enhancement following contrast administration. Adjacent meningeal enhancement was also observed. The mass encased the cavernous sinuses and internal carotid arteries bilaterally, extending superiorly through the sellar septum and compressing the optic chiasm (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Physical examination, Chest CT, and abdominal ultrasound did not found any mass or other abnormal.</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Endocrine assessment before surgery: pituitary function deteriorated further.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Report projects</th>
<th align="center" valign="top">Results</th>
<th align="center" valign="top">Normal values</th>
<th align="center" valign="top">Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Prolactin</td>
<td align="center" valign="top">0.11</td>
<td align="center" valign="top">3.34&#x2013;26.7</td>
<td align="center" valign="top">ng/mL</td>
</tr>
<tr>
<td align="left" valign="top">FT3</td>
<td align="center" valign="top">1.97</td>
<td align="center" valign="top">2.38&#x2013;4.34</td>
<td align="center" valign="top">pg/mL</td>
</tr>
<tr>
<td align="left" valign="top">FT4</td>
<td align="center" valign="top">0.70</td>
<td align="center" valign="top">0.9&#x2013;1.76</td>
<td align="center" valign="top">ng/dL</td>
</tr>
<tr>
<td align="left" valign="top">Cortisol</td>
<td align="center" valign="top">7.54 (08:00)&#x2212;4.87 (16:00)&#x2212;3.61 (00:00)</td>
<td align="center" valign="top">Morning 6.7&#x2013;22.6&#x2009;&#x03BC;g/dL; Afternoon 0&#x2013;10&#x2009;&#x03BC;g/dL</td>
<td align="center" valign="top">&#x03BC;g/dL</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p><bold>(A,B)</bold> MRI plain scan showed suprasellar irregular soft tissue signal mass; <bold>(C&#x2013;E)</bold> Enhanced MRI scan showed that the lesion was significantly enhanced, the adjacent meninges were enhanced, and the boundary was clear. The mass wrapped the cavernous sinus and the cavernous sinus segment of the internal carotid artery on both sides, broke through the sellar septum upward, and pushed the optic chiasm; <bold>(F)</bold> CTA showed abundant blood perfusion in the lesion; <bold>(G)</bold> During the operation, as we can see, the boundary of the lesion was clear, the bilateral internal carotid artery was wrapped, and the blood supply was abnormally rich.</p>
</caption>
<graphic xlink:href="fneur-14-1253821-g002.tif"/>
</fig>
<p>Given the rapid decline in vision and severe headaches of the patient. A craniotomy procedure via pterional approach was performed for the &#x201C;tumor&#x201D; resection. During the procedure, we observed that the lesion exhibited rich blood supply, firm texture, and complete encasement of the optic nerve and internal carotid artery. Consequently, a subtotal resection was performed. Postoperatively, the patient received a physiologic dose of hydrocortisone. Although she experienced complications such as diabetes insipidus and hypernatremia in the perioperative period, pituitary hormone assessment gradually returned to normal. Furthermore, postoperative headaches were alleviated, and partial restoration of vision was achieved.</p>
<p>On pathological examination, we initially performed immunohistochemical staining for CD56, syn, and cga to confirm the presence of neuroendocrine tumors; however, the results were negative. Subsequently, we continued to test for CK8/18 and CK to verify the presence of meningioma, and the results remained negative. Next, we performed immunohistochemical staining for GFAP to confirm the presence of glioma, and the results were again negative (<xref ref-type="fig" rid="fig3">Figure 3</xref>). After ruling out common lesions in the sella region, we suspected that the lesion was inflammatory. The next pathological examination revealed that the lesion was predominantly composed of lymphoid cells and plasma cells. Notably, there were more than 50 IgG4-positive plasma cells per high-power field (HPF), accounting for over 50% of the IgG-positive plasma cells. Additionally, numerous ganglion cells were identified in the specimens. These ganglion cells displayed scattered distribution, large nuclei, and abundant basophilic cytoplasm. The HE staining revealed the presence of ganglia, while immunohistochemical staining demonstrated positive labeling for S-100. Furthermore, immunohistochemistry analysis revealed positive expression of CD3, CD4, CD20, CD21 K(+), and &#x03BB;(+) (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Based on these immunohistochemical findings, including plasma cell positivity, the presence of CD3 and CD4 in the background, and an enlarged and distorted follicular network demonstrated by CD21, we were also able to confirm a diagnosis of MALT lymphom. Based on these findings, the final diagnosis was IgG4-associated hypophysitis coexisting with MALT lymphoma and gangliocytoma. The serum immunoglobulins level was not evaluated during the whole course.</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Immunohistochemical staining showed the Syn (&#x2212;), CK (&#x2212;), GFAP (&#x2212;), NeuN (&#x2212;), and Ki-67 (+ 20%).</p>
</caption>
<graphic xlink:href="fneur-14-1253821-g003.tif"/>
</fig>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p><bold>(A)</bold> The distinct fibrosclerotic background; <bold>(B)</bold> Sclerosis and hyalinization of the wall of small vessels; <bold>(C)</bold> A large number of lymphocytes; <bold>(D)</bold> Patches of plasma cells; <bold>(E,F)</bold> More than 50 IgG4positive cells per high-power field. <bold>(G)</bold> Ganglion cells under H&#x0026;E staining; <bold>(H)</bold> S-100 positivity; <bold>(I)</bold> CD 3(+); <bold>(J)</bold> CD 4(+); <bold>(K)</bold> CD 20(+); and <bold>(L)</bold> CD 21(+).</p>
</caption>
<graphic xlink:href="fneur-14-1253821-g004.tif"/>
</fig>
<p>Following the definitive diagnosis, the patient was initiated on high-dose glucocorticoid therapy: prednisone 40&#x2009;mg/day for 4&#x2009;weeks, followed by a tapering dose over the next 3&#x2009;months. We have been monitoring the patient&#x2019;s progress; unfortunately, she declined further serologic and imaging evaluations.</p>
</sec>
<sec sec-type="discussion" id="sec3">
<title>Discussion</title>
<p>We present a unique case of biopsy-proven IgG4-associated hypophysitis coexisting with MALT lymphoma and gangliocytoma, which, to the best of our knowledge, has not been reported previously. Over a span of 6&#x2009;months, the lesion in the sellar region rapidly enlarged, resulting in severe vision loss in both eyes. To preserve vision, the patient underwent emergency surgery, leading to substantial removal of the lesion. Pathological examination confirmed the diagnosis of IgG4-associated hypophysitis coexisting with MALT lymphoma and gangliocytoma. Subsequently, the patient received low-dose glucocorticoid treatment for a duration of 2&#x2009;years. During a 3-year telephone follow-up, the patient reported significant improvement in vision. Unfortunately, the patient declined further imaging studies, preventing a comparison with preoperative images.</p>
<p>IgG4-related disease is a chronic, progressive inflammatory disorder characterized by fibrosis that can affect multiple organs. It can often be misdiagnosed as malignancy, infection, or other immune-mediated diseases. The disease is characterized by mass lesions, elevated serum IgG4 levels, infiltration of IgG4-positive plasma cells, and tissue fibrosis (<xref ref-type="bibr" rid="ref2">2</xref>). At present, its pathogenesis is still unclear. Although IgG4-related disease rarely affects the brain parenchyma, the pituitary gland is one of its targets. IgG4-related hypophysitis typically presents with symptoms such as headache, visual field defects, and vision loss, which are caused by mass effect in the sellar region. Impaired pituitary function can lead to adenohypophysis and central diabetes insipidus. It is important to differentiate IgG4-related hypophysitis from other conditions such as Langerhans cell histiocytosis (LCH), sarcoidosis, granulomatosis with polyangiitis, infections, and tumors (<xref ref-type="bibr" rid="ref3">3</xref>), so pathological diagnosis is the gold standard to distinguish them. In view of the scarce prevalence of IgG4-related hypophysitis, various countries and regions utilize their respective diagnostic samples, leading to a lack of standardized guidelines. In this particular scenario, we have relied upon Leporati&#x2019;s diagnostic criteria for reference (<xref ref-type="table" rid="tab3">Table 3</xref>) (<xref ref-type="bibr" rid="ref4">4</xref>).</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Diagnostic criteria for IgG4-related hypophysitis.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Diagnostic criteria for IgG4-related hypophysitis</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Criterion 1: Pituitary histopathology</td>
</tr>
<tr>
<td align="left" valign="top">Mononuclear infiltration of the pituitary gland, rich in lymphocytes and plasma cells, with more than 10 IgG4- positive cells per high-power field</td>
</tr>
<tr>
<td align="left" valign="top">Criterion 2: Pituitary MRI</td>
</tr>
<tr>
<td align="left" valign="top">Sellar mass and/or thickened pituitary stalk</td>
</tr>
<tr>
<td align="left" valign="top">Criterion 3: Biopsy-proven involvement in other organs</td>
</tr>
<tr>
<td align="left" valign="top">Association with IgG4-positive lesions in other organs</td>
</tr>
<tr>
<td align="left" valign="top">Criterion 4: Serology</td>
</tr>
<tr>
<td align="left" valign="top">Increased serum IgG4 (140&#x2009;mg/dL)</td>
</tr>
<tr>
<td align="left" valign="top">Criterion 5: Response to glucocorticoids</td>
</tr>
<tr>
<td align="left" valign="top">Shrinkage of the pituitary mass and symptom improvement with steroids.</td>
</tr>
<tr>
<td align="left" valign="top">Diagnosis of IgG4-related hypophysitis is established when any of the following is fulfilled:</td>
</tr>
<tr>
<td align="left" valign="top">Criterion 1</td>
</tr>
<tr>
<td align="left" valign="top">Criteria 2 and 3</td>
</tr>
<tr>
<td align="left" valign="top">Criteria 2, 4, and 5</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>For the diagnosis of the case, firstly, in the histopathological examination, the presence of mononuclear infiltration in the pituitary gland, characterized by abundant lymphocytes and plasma cells, with over 10 IgG4-positive cells per high-power field, fulfills Leporati&#x2019;s diagnostic criterion 1. Secondly, the patient underwent MRI examination, revealing the presence of a mass in the sellar region. Although no thickening of the pituitary stalk was identified, this finding largely satisfies Leporati&#x2019;s diagnostic criterion 2. Thirdly, our patient received glucocorticoid therapy, and although no imaging examination was conducted, there was evident improvement in symptoms, which also substantially meets Leporati&#x2019;s diagnostic criterion 5. Lastly, confirmation of the diagnosis requires meeting diagnostic criterion 1 alone, thus establishing this as a case of IgG4-related hypophysitis.</p>
<p>Differentiation of IgG4-related hypophysitis from other rare diseases in the sellar region is still necessary. One such disease is mixed pituitary adenoma-gangliocytoma, which predominantly affects female patients and is characterized by the secretion of one or more pituitary hormones, including growth hormone (GH) and prolactin (PLR), with a higher prevalence of growth hormone secretion (<xref ref-type="bibr" rid="ref5">5</xref>). Diagnosis of this disease primarily relies on pathological examination. However, in our case, the patient did not display hormone hypersecretion, and the pathological examination did not reveal pituitary adenoma-associated cells, leading us to exclude the possibility of a mixed pituitary adenoma-gangliocytoma. Another infrequent sellar region disease is hypothalamic hamartoma, which is more commonly seen in infants and children. It is characterized by congenital abnormal brain tissue development and presents mainly with precocious puberty and epilepsy as clinical manifestations (<xref ref-type="bibr" rid="ref6">6</xref>). Pathological examination of this disease shows an absence of solid tumor components but mainly consists of mature neurons and glial cells. Taking into account the patient&#x2019;s age, medical history, and pathological findings, we ruled out this condition.</p>
<p>Glucocorticoids are currently recommended as the first-line treatment for IgG4-related disease, unless contraindications are present (<xref ref-type="bibr" rid="ref7">7</xref>). Our patient responded well to glucocorticoid therapy, with significant improvement in pituitary function and partial recovery of vision. The use of glucocorticoids may vary in different regions. In most cases, prednisone at a dose of 30&#x2013;40&#x2009;mg/day is commonly used as an initial treatment, which is then gradually tapered over a period of 2&#x2013;4&#x2009;weeks. Glucocorticoid therapy is typically discontinued after 3&#x2013;6&#x2009;months. However, some researchers have suggested low-dose maintenance therapy with glucocorticoids for up to 3&#x2009;years to maximize patient benefits (<xref ref-type="bibr" rid="ref8">8</xref>).</p>
<p>Mucosa-associated lymphoid tissue (MALT) lymphoma, first reported in 1984, demonstrates a slow clinical progression (<xref ref-type="bibr" rid="ref9">9</xref>). While MALT lymphoma primarily occurs in the stomach, recent studies have reported an increasing number of cases in ocular adnexal, cutaneous, pulmonary, and sella regions (<xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref11">11</xref>). Sellar MALT lymphoma is an extremely rare condition. It is categorized as a low-grade malignant lymphoma distinguished by its unique etiology, pathological characteristics, and favorable prognosis. The pathogenesis of MALT lymphoma in the sellar region remains unknown, although several studies have suggested a link between MALT lymphoma and chronic infections and autoimmune diseases (<xref ref-type="bibr" rid="ref12">12</xref>). Additionally, research has proposed a potential association between MALT lymphoma and IgG-related diseases (<xref ref-type="bibr" rid="ref13">13</xref>). In this particular case, the presence of IgG4-related inflammation, plasma cells on pathological examination, and the expression of CD3 and CD4 cells in the background, as well as an enlarged and distorted follicular network on CD21 positivity, ultimately led to the diagnosis of MALT lymphoma.</p>
<p>Gangliocytomas are rare and benign neuronal cell tumors that are predominantly found in the hypothalamic and sellar regions. They often coexist with pituitary adenomas, mainly of the growth hormone (GH) type (<xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref15">15</xref>). Since its first report by Kiyono in 1926, over 100 cases of pituitary adenoma combined with gangliocytoma have been reported worldwide (<xref ref-type="bibr" rid="ref16">16</xref>&#x2013;<xref ref-type="bibr" rid="ref18">18</xref>). Currently, diagnosing gangliocytoma based on clinical and radiological elements is challenging. Moreover, due to its frequent association with pituitary adenomas, gangliocytoma is often overlooked in pathological examinations (<xref ref-type="bibr" rid="ref19">19</xref>).</p>
<p>The origin of gangliocytoma remains unclear, and there are three hypotheses regarding its mechanism of development: (1) it originates from the hypothalamus and produces growth hormone-releasing hormone, leading to hyperplasia of pituitary cells (<xref ref-type="bibr" rid="ref20">20</xref>, <xref ref-type="bibr" rid="ref21">21</xref>); (2) it originates from primitive stem/progenitor cells of the adenohypophysis (<xref ref-type="bibr" rid="ref17">17</xref>, <xref ref-type="bibr" rid="ref22">22</xref>); (3) it arises from neuronal transformation within adenoma cells, as evidenced by intermediate structures observed between adenoma cells and ganglion cells in ultrastructural studies (<xref ref-type="bibr" rid="ref23">23</xref>). However, the presence of IgG4-associated inflammation with ganglion cells and the absence of pituitary adenoma cells in our case do not align with any of these hypotheses. Therefore, we speculate that the cellular origin of ganglion cells may also be related to inflammatory or immune functions, which requires further investigation.</p>
<p>In conclusion, we report the first case of biopsy-proven IgG4-related hypophysitis accompanied by MALT lymphoma and gangliocytoma. Although the patient did not fully recover pituitary function and vision, her headaches were significantly relieved, and disease progression was prevented through surgical and medical interventions. We hope that our treatment approach can provide valuable insights and guidance for future cases.</p>
</sec>
<sec sec-type="data-availability" id="sec4">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="sec5">
<title>Ethics statement</title>
<p>The studies involving human participants were reviewed and approved by Ethics Committee of General Hospital of Western Theater Command. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec sec-type="author-contributions" id="sec6">
<title>Author contributions</title>
<p>DZ: Investigation, Writing &#x2013; original draft. LJ: Conceptualization, Writing &#x2013; original draft. TY: Writing &#x2013; review &#x0026; editing. JC: Supervision, Validation, Writing &#x2013; review &#x0026; editing. YM: Project administration, Resources, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec18">
<title>Funding</title>
<p>The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Hospital Foundation of General Hospital of Western Theater Command (2021-XZYG-A13 to YM).</p>
</sec>
<sec sec-type="COI-statement" id="sec7">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Lojou</surname>
<given-names>M</given-names>
</name> <name>
<surname>Bonneville</surname>
<given-names>JF</given-names>
</name> <name>
<surname>Ebbo</surname>
<given-names>M</given-names>
</name> <name>
<surname>Schleinitz</surname>
<given-names>N</given-names>
</name> <name>
<surname>Castinetti</surname>
<given-names>F</given-names>
</name></person-group>. <article-title>IgG4 hypophysitis: diagnosis and management</article-title>. <source>Presse Med</source>. (<year>2020</year>) <volume>49</volume>:<fpage>104016</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lpm.2020.104016</pub-id>, PMID: <pub-id pub-id-type="pmid">32234384</pub-id></citation>
</ref>
<ref id="ref2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Lanzillotta</surname>
<given-names>M</given-names>
</name> <name>
<surname>Mancuso</surname>
<given-names>G</given-names>
</name> <name>
<surname>Della-Torre</surname>
<given-names>E</given-names>
</name></person-group>. <article-title>Advances in the diagnosis and management of IgG4 related disease</article-title>. <source>BMJ</source>. (<year>2020</year>) <volume>369</volume>:<fpage>m1067</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.m1067</pub-id></citation>
</ref>
<ref id="ref3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>AbdelRazek</surname>
<given-names>MA</given-names>
</name> <name>
<surname>Venna</surname>
<given-names>N</given-names>
</name> <name>
<surname>Stone</surname>
<given-names>JH</given-names>
</name></person-group>. <article-title>IgG4-related disease of the central and peripheral nervous systems</article-title>. <source>Lancet Neurol</source>. (<year>2018</year>) <volume>17</volume>:<fpage>183</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(17)30471-4</pub-id>, PMID: <pub-id pub-id-type="pmid">29413316</pub-id></citation>
</ref>
<ref id="ref4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Leporati</surname>
<given-names>P</given-names>
</name> <name>
<surname>Landek-Salgado</surname>
<given-names>MA</given-names>
</name> <name>
<surname>Lupi</surname>
<given-names>I</given-names>
</name> <name>
<surname>Chiovato</surname>
<given-names>L</given-names>
</name> <name>
<surname>Caturegli</surname>
<given-names>P</given-names>
</name></person-group>. <article-title>IgG4-related hypophysitis: a new addition to the hypophysitis spectrum</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2011</year>) <volume>96</volume>:<fpage>1971</fpage>&#x2013;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1210/jc.2010-2970</pub-id>, PMID: <pub-id pub-id-type="pmid">21593109</pub-id></citation>
</ref>
<ref id="ref5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Lopes</surname>
<given-names>MB</given-names>
</name> <name>
<surname>Sloan</surname>
<given-names>E</given-names>
</name> <name>
<surname>Polder</surname>
<given-names>J</given-names>
</name></person-group>. <article-title>Mixed gangliocytoma-pituitary adenoma: insights on the pathogenesis of a rare sellar tumor</article-title>. <source>Am J Surg Pathol</source>. (<year>2017</year>) <volume>41</volume>:<fpage>586</fpage>&#x2013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1097/PAS.0000000000000806</pub-id></citation>
</ref>
<ref id="ref6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Kerrigan</surname>
<given-names>JF</given-names>
</name> <name>
<surname>Parsons</surname>
<given-names>A</given-names>
</name> <name>
<surname>Tsang</surname>
<given-names>C</given-names>
</name> <name>
<surname>Simeone</surname>
<given-names>K</given-names>
</name> <name>
<surname>Coons</surname>
<given-names>S</given-names>
</name> <name>
<surname>Wu</surname>
<given-names>J</given-names>
</name></person-group>. <article-title>Hypothalamic hamartoma: neuropathology and epileptogenesis</article-title>. <source>Epilepsia</source>. (<year>2017</year>) <volume>58</volume>:<fpage>22</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1111/epi.13752</pub-id>, PMID: <pub-id pub-id-type="pmid">28591478</pub-id></citation>
</ref>
<ref id="ref7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Khosroshahi</surname>
<given-names>A</given-names>
</name> <name>
<surname>Wallace</surname>
<given-names>ZS</given-names>
</name> <name>
<surname>Crowe</surname>
<given-names>JL</given-names>
</name> <name>
<surname>Akamizu</surname>
<given-names>T</given-names>
</name> <name>
<surname>Azumi</surname>
<given-names>A</given-names>
</name> <name>
<surname>Carruthers</surname>
<given-names>MN</given-names>
</name> <etal/></person-group>. <article-title>International consensus guidance statement on the management and treatment of IgG4-related disease</article-title>. <source>Arthritis Rheum</source>. (<year>2015</year>) <volume>67</volume>:<fpage>1688</fpage>&#x2013;<lpage>99</lpage>. doi: <pub-id pub-id-type="doi">10.1002/art.39132</pub-id>, PMID: <pub-id pub-id-type="pmid">25809420</pub-id></citation>
</ref>
<ref id="ref8">
<label>8.</label>
<citation citation-type="other"><person-group person-group-type="author"><collab id="coll1">The Working Committee of the Japan Pancreas Society and the Research Committee for Intractable Pancreatic Disease supported by the Ministry of Health, Labour and Welfare of Japan</collab><name>
<surname>Kamisawa</surname>
<given-names>T</given-names>
</name> <name>
<surname>Okazaki</surname>
<given-names>K</given-names>
</name> <name>
<surname>Kawa</surname>
<given-names>S</given-names>
</name> <name>
<surname>Ito</surname>
<given-names>T</given-names>
</name> <name>
<surname>Inui</surname>
<given-names>K</given-names>
</name> <etal/></person-group>. <article-title>Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis</article-title>. <source>J Gastroenterol</source>. (<year>2014</year>) <volume>49</volume>:<fpage>961</fpage>&#x2013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00535-014-0945-z</pub-id>, PMID: <pub-id pub-id-type="pmid">24639058</pub-id></citation>
</ref>
<ref id="ref9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Isaacson</surname>
<given-names>P</given-names>
</name> <name>
<surname>Wright</surname>
<given-names>DH</given-names>
</name></person-group>. <article-title>Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue</article-title>. <source>Cancer</source>. (<year>1984</year>) <volume>53</volume>:<fpage>2515</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1002/1097-0142(19840601)53:11&#x003C;2515::AID-CNCR2820531125&#x003E;3.0.CO;2-C</pub-id></citation>
</ref>
<ref id="ref10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Cai</surname>
<given-names>S</given-names>
</name> <name>
<surname>Xiao</surname>
<given-names>J</given-names>
</name> <name>
<surname>Chen</surname>
<given-names>P</given-names>
</name> <name>
<surname>Luo</surname>
<given-names>H</given-names>
</name> <name>
<surname>Cheng</surname>
<given-names>Z</given-names>
</name></person-group>. <article-title>Primary pituitary stalk mucosa-associated lymphoid tissue lymphoma: a case report and literature review</article-title>. <source>Front Neurol</source>. (<year>2023</year>) <volume>14</volume>:<fpage>1193391</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2023.1193391</pub-id>, PMID: <pub-id pub-id-type="pmid">37554391</pub-id></citation>
</ref>
<ref id="ref11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</name> <name>
<surname>Hojo</surname>
<given-names>M</given-names>
</name></person-group>. <article-title>Diagnosis and treatment for gastric mucosa-associated lymphoid tissue (MALT) lymphoma</article-title>. <source>J Clin Med</source>. (<year>2022</year>) <volume>12</volume>:<fpage>120</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm12010120</pub-id>, PMID: <pub-id pub-id-type="pmid">36614921</pub-id></citation>
</ref>
<ref id="ref12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Joshi</surname>
<given-names>M</given-names>
</name> <name>
<surname>Sheikh</surname>
<given-names>H</given-names>
</name> <name>
<surname>Abbi</surname>
<given-names>K</given-names>
</name> <name>
<surname>Long</surname>
<given-names>S</given-names>
</name> <name>
<surname>Sharma</surname>
<given-names>K</given-names>
</name> <name>
<surname>Tulchinsky</surname>
<given-names>M</given-names>
</name> <etal/></person-group>. <article-title>Marginal zone lymphoma: old, new, targeted, and epigenetic therapies</article-title>. <source>Ther Adv Hematol</source>. (<year>2012</year>) <volume>3</volume>:<fpage>275</fpage>&#x2013;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1177/2040620712453595</pub-id>, PMID: <pub-id pub-id-type="pmid">23616915</pub-id></citation>
</ref>
<ref id="ref13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Nakayama</surname>
<given-names>R</given-names>
</name> <name>
<surname>Matsumoto</surname>
<given-names>Y</given-names>
</name> <name>
<surname>Horiike</surname>
<given-names>S</given-names>
</name> <name>
<surname>Kobayashi</surname>
<given-names>S</given-names>
</name> <name>
<surname>Nakao</surname>
<given-names>R</given-names>
</name> <name>
<surname>Nagoshi</surname>
<given-names>H</given-names>
</name> <etal/></person-group>. <article-title>Close pathogenetic relationship between ocular immunoglobulin G4-related disease (IgG4-RD) and ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma</article-title>. <source>Leuk Lymphoma</source>. (<year>2014</year>) <volume>55</volume>:<fpage>1198</fpage>&#x2013;<lpage>202</lpage>. doi: <pub-id pub-id-type="doi">10.3109/10428194.2013.823494</pub-id>, PMID: <pub-id pub-id-type="pmid">23841508</pub-id></citation>
</ref>
<ref id="ref14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Puchner</surname>
<given-names>MJ</given-names>
</name> <name>
<surname>L&#x00FC;decke</surname>
<given-names>DK</given-names>
</name> <name>
<surname>Saeger</surname>
<given-names>W</given-names>
</name> <name>
<surname>Riedel</surname>
<given-names>M</given-names>
</name> <name>
<surname>Asa</surname>
<given-names>SL</given-names>
</name></person-group>. <article-title>Gangliocytomas of the sellar region&#x2014;a review</article-title>. <source>Exp Clin Endocrinol Diabetes</source>. (<year>1995</year>) <volume>103</volume>:<fpage>129</fpage>&#x2013;<lpage>49</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0029-1211342</pub-id>, PMID: <pub-id pub-id-type="pmid">7584515</pub-id></citation>
</ref>
<ref id="ref15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Sakata</surname>
<given-names>K</given-names>
</name> <name>
<surname>Fujimori</surname>
<given-names>K</given-names>
</name> <name>
<surname>Komaki</surname>
<given-names>S</given-names>
</name> <name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name> <name>
<surname>Sugita</surname>
<given-names>Y</given-names>
</name> <name>
<surname>Ashida</surname>
<given-names>K</given-names>
</name> <etal/></person-group>. <article-title>Pituitary Gangliocytoma producing TSH and TRH: a review of "Gangliocytomas of the Sellar region"</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2020</year>) <volume>105</volume>:<fpage>3109</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1210/clinem/dgaa474</pub-id>, PMID: <pub-id pub-id-type="pmid">32706866</pub-id></citation>
</ref>
<ref id="ref16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Geddes</surname>
<given-names>JF</given-names>
</name> <name>
<surname>Jansen</surname>
<given-names>GH</given-names>
</name> <name>
<surname>Robinson</surname>
<given-names>SFD</given-names>
</name> <name>
<surname>G&#x00F6;m&#x00F6;ri</surname>
<given-names>E</given-names>
</name> <name>
<surname>Holton</surname>
<given-names>JL</given-names>
</name> <name>
<surname>Monson</surname>
<given-names>JP</given-names>
</name> <etal/></person-group>. <article-title>'Gangliocytomas' of the pituitary: a heterogeneous group of lesions with differing histogenesis</article-title>. <source>Am J Surg Pathol</source>. (<year>2000</year>) <volume>24</volume>:<fpage>607</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00000478-200004000-00017</pub-id></citation>
</ref>
<ref id="ref17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Kontogeorgos</surname>
<given-names>G</given-names>
</name> <name>
<surname>Mourouti</surname>
<given-names>G</given-names>
</name> <name>
<surname>Kyrodimou</surname>
<given-names>E</given-names>
</name> <name>
<surname>Liapi-Avgeri</surname>
<given-names>G</given-names>
</name> <name>
<surname>Parasi</surname>
<given-names>E</given-names>
</name></person-group>. <article-title>Ganglion cell containing pituitary adenomas: signs of neuronal differentiation in adenoma cells</article-title>. <source>Acta Neuropathol</source>. (<year>2006</year>) <volume>112</volume>:<fpage>21</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-006-0055-y</pub-id>, PMID: <pub-id pub-id-type="pmid">16699777</pub-id></citation>
</ref>
<ref id="ref18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Mikami</surname>
<given-names>S</given-names>
</name> <name>
<surname>Kameyama</surname>
<given-names>K</given-names>
</name> <name>
<surname>Takahashi</surname>
<given-names>S</given-names>
</name> <name>
<surname>Yoshida</surname>
<given-names>K</given-names>
</name> <name>
<surname>Kawase</surname>
<given-names>T</given-names>
</name> <name>
<surname>Sano</surname>
<given-names>T</given-names>
</name> <etal/></person-group>. <article-title>Combined gangliocytoma and prolactinoma of the pituitary gland</article-title>. <source>Endocr Pathol</source>. (<year>2008</year>) <volume>19</volume>:<fpage>117</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12022-008-9027-1</pub-id>, PMID: <pub-id pub-id-type="pmid">18651251</pub-id></citation>
</ref>
<ref id="ref19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Balci</surname>
<given-names>S</given-names>
</name> <name>
<surname>Saglam</surname>
<given-names>A</given-names>
</name> <name>
<surname>Oruckaptan</surname>
<given-names>H</given-names>
</name> <name>
<surname>Erbas</surname>
<given-names>T</given-names>
</name> <name>
<surname>Soylemezoglu</surname>
<given-names>F</given-names>
</name></person-group>. <article-title>Pituitary adenoma with gangliocytic component: report of 5 cases with focus on immunoprofile of gangliocytic component</article-title>. <source>Pituitary</source>. (<year>2015</year>) <volume>18</volume>:<fpage>23</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11102-013-0551-8</pub-id>, PMID: <pub-id pub-id-type="pmid">24430434</pub-id></citation>
</ref>
<ref id="ref20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Kurosaki</surname>
<given-names>M</given-names>
</name> <name>
<surname>Saeger</surname>
<given-names>W</given-names>
</name> <name>
<surname>Ludecke</surname>
<given-names>DK</given-names>
</name></person-group>. <article-title>Intrasellar gangliocytomas associated with acromegaly</article-title>. <source>Brain Tumor Pathol</source>. (<year>2002</year>) <volume>19</volume>:<fpage>63</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF02478929</pub-id></citation>
</ref>
<ref id="ref21">
<label>21.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Saeger</surname>
<given-names>W</given-names>
</name> <name>
<surname>Puchner</surname>
<given-names>MJ</given-names>
</name> <name>
<surname>Ludecke</surname>
<given-names>DK</given-names>
</name></person-group>. <article-title>Combined sellar gangliocytoma and pituitary adenoma in acromegaly or Cushing's disease. A report of 3 cases</article-title>. <source>Virchows Arch</source>. (<year>1994</year>) <volume>425</volume>:<fpage>93</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF00193956</pub-id>, PMID: <pub-id pub-id-type="pmid">7921420</pub-id></citation>
</ref>
<ref id="ref22">
<label>22.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Chen</surname>
<given-names>J</given-names>
</name> <name>
<surname>Hersmus</surname>
<given-names>N</given-names>
</name> <name>
<surname>Duppen</surname>
<given-names>VV</given-names>
</name> <name>
<surname>Caesens</surname>
<given-names>P</given-names>
</name> <name>
<surname>Denef</surname>
<given-names>C</given-names>
</name> <name>
<surname>Vankelecom</surname>
<given-names>H</given-names>
</name></person-group>. <article-title>The adult pituitary contains a cell population displaying stem/progenitor cell and early embryonic characteristics</article-title>. <source>Endocrinology</source>. (<year>2005</year>) <volume>146</volume>:<fpage>3985</fpage>&#x2013;<lpage>98</lpage>. doi: <pub-id pub-id-type="doi">10.1210/en.2005-0185</pub-id>, PMID: <pub-id pub-id-type="pmid">15932930</pub-id></citation>
</ref>
<ref id="ref23">
<label>23.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name>
<surname>Vidal</surname>
<given-names>S</given-names>
</name> <name>
<surname>Horvath</surname>
<given-names>E</given-names>
</name> <name>
<surname>Kovacs</surname>
<given-names>K</given-names>
</name> <name>
<surname>Lloyd</surname>
<given-names>RV</given-names>
</name> <name>
<surname>Smyth</surname>
<given-names>HS</given-names>
</name></person-group>. <article-title>Reversible transdifferentiation: interconversion of somatotrophs and lactotrophs in pituitary hyperplasia</article-title>. <source>Mod Pathol</source>. (<year>2001</year>) <volume>14</volume>:<fpage>20</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1038/modpathol.3880252</pub-id></citation>
</ref>
</ref-list>
</back>
</article>